<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="48">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on December 16, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05160519</url>
  </required_header>
  <id_info>
    <org_study_id>MMDU/IEC/2157</org_study_id>
    <secondary_id>U1111-1270-8393</secondary_id>
    <nct_id>NCT05160519</nct_id>
  </id_info>
  <brief_title>Class IV Laser Therapy on Ejection Fraction, Cardio Biomarkers and Functional Outcomes</brief_title>
  <official_title>Class IV Laser Therapy on Ejection Fraction, Cardio Biomarkers and Functional Outcomes Among Individuals With Acute Coronary Syndrome</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Asir John Samuel</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Maharishi Markendeswar University (Deemed to be University)</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Maharishi Markendeswar University (Deemed to be University)</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      A total of 86 Individuals with Acute coronary Syndrome who underwent angioplasty with or&#xD;
      without stent will be recruited by purposive sampling method in a randomized double-blinded&#xD;
      sham controlled trial. Recruited participants will be divided into two group of equal size (n&#xD;
      = 43): Sham control group and experimental group by block randomization. The experimental&#xD;
      group will subject to Class IV laser therapy along with the standard treatment regime at&#xD;
      three spot(s) over the pericardium (left parasternal 2nd, 3rd intercostal space and apex) for&#xD;
      a duration of 60 seconds at each point.; immediately after the angioplasty and subsequent two&#xD;
      days. Left ventricular ejection fraction, cardiac biomarkers (CK-MB &amp; Troponin I) and&#xD;
      functional outcomes will be assessed at base line and after 3 days post-interventions.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Individuals with acute coronary syndrome admitted in the Cardiac Care Unit of MMIMSR,&#xD;
      Mullana, Ambala, Haryana who underwent angioplasty with or without stent during the study&#xD;
      period will be screened according to selection criteria. Then the invited participants will&#xD;
      be asked to sign a written informed consent for their voluntarily participation in the study.&#xD;
      Participants will be divided into two group of equal size (n = 43): Sham control group and&#xD;
      experimental group by block randomization. The researcher will be divided into therapist and&#xD;
      evaluator or assessor. The therapist will responsible for conducting the therapy and&#xD;
      evaluator or assessor will responsible for assessment of outcome measures both pre and post&#xD;
      intervention. All the assessor or evaluator (lab technicians who assess cardiac biomarkers,&#xD;
      Cardiologist who perform echocardiography and assess ECG) will be blinded from the grouping&#xD;
      of the participants. The participants will also be blinded to the study by use of laser&#xD;
      protected eye wears. Left ventricular ejection fraction, cardiac biomarkers (CK-MB &amp; Troponin&#xD;
      I) and functional outcomes will be assessed at base line. The experimental group will subject&#xD;
      to Class IV laser therapy along with the standard treatment regime at three spot(s) over the&#xD;
      pericardium (left parasternal 2nd, 3rd intercostal space and apex) for a duration of 60&#xD;
      seconds at each point.; immediately after the angioplasty and subsequent two days. The sham&#xD;
      group will subject to irradiation but the equipment will be kept off. All the outcomes&#xD;
      measures will be reassess after 3 days post-interventions.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">January 10, 2022</start_date>
  <completion_date type="Anticipated">September 30, 2023</completion_date>
  <primary_completion_date type="Anticipated">March 30, 2023</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Left Ventricular Ejection Fraction</measure>
    <time_frame>changes will be measured at baseline and on 3rd day post intervention</time_frame>
    <description>Left Ventricular ejection fraction is a is a direct indicator of left ventricle systolic function.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Cardiac Biomarkers</measure>
    <time_frame>changes will be measured at baseline and on 3rd day post intervention</time_frame>
    <description>Cardiac Biomarkers (CK-MB, Troponin I) are the early markers of acute myocardial injury</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Functional outcomes</measure>
    <time_frame>changes will be measured at baseline and on 3rd day post intervention</time_frame>
    <description>Hindi version of Seattle angina Questionnaire will be used to assess functional outcomes</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">86</enrollment>
  <condition>Acute Coronary Syndrome</condition>
  <arm_group>
    <arm_group_label>Experimental</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>43 participants will be irradiated with Class IV laser therapy over the left parasternal area to improve ejection fraction, cardio biomarkers.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Sham Controlled</arm_group_label>
    <arm_group_type>Sham Comparator</arm_group_type>
    <description>43 participants will subject to irradiation but the equipment will be kept off.</description>
  </arm_group>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>Class IV Laser</intervention_name>
    <description>43 participants will be irradiated with Class IV laser therapy over the left parasternal area to improve ejection fraction, cardio biomarkers.&#xD;
Device: Litecure LCT-1000C Class IV laser will be used in contact method over the left parasternal area in 2nd, 3rd intercostal space and apex. Dosage and Parameters for the irradiation will be calculated. Parameters: 1. Wavelength: 980nm, 2. Power/ Energy density: 6W/6J/cm2 3. Frequency: 2500Hz 4. Energy delivered at each spot: 360J 5. irradiation spots: 3 6. Irradiation time: 60 sec at each spot.&#xD;
Both the patient and laser giver will use the laser protected eye wears to ensure standard practice for the laser.</description>
    <arm_group_label>Experimental</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>Sham Class IV Laser</intervention_name>
    <description>43 participants will be irradiated with Class IV laser therapy over the left parasternal area to improve ejection fraction, cardio biomarkers.&#xD;
Device: Litecure LCT-1000C Class IV laser will be placed over the left parasternal area in 2nd, 3rd intercostal space and apex without switching on the instrument.&#xD;
Both the patient and laser giver will use the laser protected eye wears to ensure standard practice for the laser.</description>
    <arm_group_label>Sham Controlled</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Individuals with Acute Coronary Syndrome (ACS) who underwent angioplasty with or&#xD;
             without stent,&#xD;
&#xD;
          2. Both male and female above 18 years of age,&#xD;
&#xD;
          3. Hemodynamically stable,&#xD;
&#xD;
          4. Who voluntarily signed the informed consent.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Tumor or growth around mediastinum,&#xD;
&#xD;
          2. Temporary or permanent pacemaker,&#xD;
&#xD;
          3. Receiving steroids or photosensitive drugs,&#xD;
&#xD;
          4. Pregnancy,&#xD;
&#xD;
          5. Epilepsy,&#xD;
&#xD;
          6. LVEF â‰¤ 30%&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Mandeep K Jangra, PhD Scholar</last_name>
    <role>Principal Investigator</role>
    <affiliation>M.M. Institute of Physiotherapy &amp; Rehabilitation, (Maharishi Markandeshwar Deemed to be University)</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Asir J Samuel, PhD</last_name>
    <role>Study Director</role>
    <affiliation>M.M. Institute of Physiotherapy &amp; Rehabilitation, (Maharishi Markandeshwar Deemed to be University)</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Anupam Bhambhani, DM</last_name>
    <role>Study Director</role>
    <affiliation>MMIMSR, Maharishi Markandeshwar Deemed to be University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Mandeep K Jangra, PhD Scholar</last_name>
    <phone>9416797708</phone>
    <email>mjangra708@gmail.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Asir J Samuel, PhD</last_name>
    <phone>8059930222</phone>
    <email>asirjohnsamuel@mmumullana.org</email>
  </overall_contact_backup>
  <reference>
    <citation>Liebert A, Krause A, Goonetilleke N, Bicknell B, Kiat H. A Role for Photobiomodulation in the Prevention of Myocardial Ischemic Reperfusion Injury: A Systematic Review and Potential Molecular Mechanisms. Sci Rep. 2017 Feb 9;7:42386. doi: 10.1038/srep42386. Review.</citation>
    <PMID>28181487</PMID>
  </reference>
  <reference>
    <citation>Kazemi Khoo N, Babazadeh K, Lajevardi M, Dabaghian FH, Mostafavi E. Application of Low-Level Laser Therapy Following Coronary Artery Bypass Grafting (CABG) Surgery. J Lasers Med Sci. 2014 Spring;5(2):86-91.</citation>
    <PMID>25653805</PMID>
  </reference>
  <reference>
    <citation>Elbaz-Greener G, Sud M, Tzuman O, Leitman M, Vered Z, Ben-Dov N, Oron U, Blatt A. Adjunctive laser-stimulated stem-cells therapy to primary reperfusion in acute myocardial infarction in humans: Safety and feasibility study. J Interv Cardiol. 2018 Dec;31(6):711-716. doi: 10.1111/joic.12539. Epub 2018 Jul 12.</citation>
    <PMID>29999208</PMID>
  </reference>
  <reference>
    <citation>Quirk BJ, Sonowal P, Jazayeri MA, Baker JE, Whelan HT. Cardioprotection from ischemia-reperfusion injury by near-infrared light in rats. Photomed Laser Surg. 2014 Sep;32(9):505-11. doi: 10.1089/pho.2014.3743. Epub 2014 Aug 5.</citation>
    <PMID>25093393</PMID>
  </reference>
  <verification_date>December 2021</verification_date>
  <study_first_submitted>December 2, 2021</study_first_submitted>
  <study_first_submitted_qc>December 2, 2021</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 16, 2021</study_first_posted>
  <last_update_submitted>December 2, 2021</last_update_submitted>
  <last_update_submitted_qc>December 2, 2021</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 16, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Maharishi Markendeswar University (Deemed to be University)</investigator_affiliation>
    <investigator_full_name>Asir John Samuel</investigator_full_name>
    <investigator_title>Associate Professor</investigator_title>
  </responsible_party>
  <keyword>Class IV Laser, ACS, Ejection fraction, Cardiac Biomarkers</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Acute Coronary Syndrome</mesh_term>
    <mesh_term>Syndrome</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

